logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Clobetasol propionate for postoperative pain and inflammation associated with cataract surgery

< Back

Clobetasol propionate for postoperative pain and inflammation associated with cataract surgery

Drugs

Eye Disease

December 2020


Clobetasol propionate ophthalmic nanoemulsion is in development for the treatment of post-operative pain or inflammation following cataract surgery. A cataract is a cloudy area in the lens, which can develop slowly and progress to general loss of transparency, which may lead to functional impairment and visual deterioration. Cataract surgery is the only effective treatment to improve or maintain vision, however, inflammation and pain are common difficulties following this treatment.

Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil in water solution that delivers the drug clobetasol propionate directly into the eye to treat inflammation and pain associated with cataract surgery. This technology promotes anti-inflammatory genes by binding to glucocorticoid receptors. If licensed, this treatment will offer an additional option for adults with postoperative pain and inflammation following cataract surgery.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts